Cancer Research Blog

Bringing You the Latest in the Search For a Cure

Month: May 2016

Venetoclax Approved for Some Patients with Chronic Lymphocytic Leukemia

The Food and Drug Administration (FDA) approved venetoclax (Venclexta®) on April 11 for patients with chronic lymphocytic leukemia (CLL) whose tumors have a specific genetic alteration.

The accelerated approval is for patients with CLL whose tumor cells are missing a portion of chromosome 17, commonly referred to as a 17p deletion, and who have received at least one prior therapy for their cancer.

After Rising for Decades, Thyroid Cancer Incidence Stabilizes

After rising steadily for decades, the incidence of thyroid cancer in the United States may have stabilized, according to a new study. Although still increasing, the number off new cases has risen at a much slower rate in recent years than in the past.

The incidence of thyroid cancer in the United States began to rise during the early 1990s, with incidence in 2013 triple that of 30 years earlier. But the new analysis found that incidence began to level off in 2009 and remained relatively stable through 2012. The findings appeared April 14 in JAMA Otolaryngology-Head & Neck Surgery.

Calling on Data Enthusiasts to Help Advance Cancer Research

Health data enthusiasts of all stripes have arrived in Washington, DC, for an annual event known as Health Datapalooza. Incredibly smart participants from government, academia, companies, startups, and patient groups meet to share ideas and brainstorm about how to share and unleash health information to improve health outcomes for all.

Although the meeting is broader than any single disease, it will explore a topic that is central to NCI’s efforts against cancer: creating knowledge from data. And the institute is reaching out to the data innovation community to help us do just that.

Bringing global cancer leaders together at the 4th Annual Symposium on Global Cancer Research

With another passing year, we can celebrate yet another successful Annual Symposium on Global Cancer Research. The event was developed with a special focus on innovative and low-cost technologies in global cancer control, and brought inspiring keynote speakers such as John Seffrin, Former CEO of the American Cancer Society, and Tom Bollyky, Senior Fellow for Global Health at the Council on Foreign Relations. John Seffrin shared insights on what it will take to bring cancer under control this century. Specifically, he highlighting the need for continued resources, collaboration and policy change to facilitate improved access to cancer care, effective prevention strategies, and conduct innovative research. Tom Bollyky carried this discussion forward by presenting poignant data on the growing burden of cancer globally, and made a strong case to increase investments in cancer control, particularly in low- and middle-income countries.

The two panels that followed these keynotes highlighted the role of technology and data in improving cancer care all along the continuum of cancer care: from prevention, screening, early detection, diagnosis, treatment, through palliative care. Our panelists shared their successes and challenges of serving and researching in low-resource settings, discussed the role of molecular diagnostics, and reflected on effective therapies and approaches in cancer care. The poster session included demonstrations of low-cost technologies and innovations, highlighting the potential of innovative thinking, user-friendly designs, and technologies to save lives, even in low-resource settings. In the afternoon, we heard from four dedicated low- and middle-income country researchers who are actively conducting cancer control research in Myanmar, Tanzania, Guatemala, and Malawi.

Cancer Research Blog © 2016
Frontier Theme